Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.
Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.
